Liposomes for treatment of B-cell and T-cell disorders

• US 5,620,689 A
• Filed: 06/07/1995
• Issued: 04/15/1997
• Est. Priority Date: 10/20/1989
• Status: Expired due to Term

• Current Assignee: SEQUUS Pharmaceuticals, Inc. (Johnson & Johnson)
• Original Assignee: SEQUUS Pharmaceuticals, Inc. (Johnson & Johnson)
• Inventors: Martin, Francis J., Allen, Theresa M.
• Primary Examiner(s): Eisenschenk, Frank C.
• Application Number:
  US08/475,050
• Time in Patent Office: 678 Days
• Field of Search: 424/178.1, 424/181, 424/450, 424/812, 530/391.7
• US Class Current: 424/178.1
• CPC Class Codes: A61K 47/68 the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 47/6913 the liposome being modified on its surface by an antibody
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: Y10S 424/812 Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Abstract

A method of treating a subject having a disorder characterized by a neoplasm of B-lymphocyte or T-lymphocyte lineage cells is described. The method includes administering a suspension of liposomes having a surface coating of polyethylene glycol chains. Attached to the distal ends of the chains are antibodies or antibody fragments effective to bind to an antigen specific to the affected cells. In one embodiment, anti-CD19 antibodies are attached to the liposome-bound chains, for treatment of multiple myeloma.

Claims

1. A method of treating a subject having a disorder characterized by a neoplasm of B-lymphocyte lineage cells or T-lymphocyte lineage cells, comprising

administering to the subject, a suspension of liposomes having a surface coating of polyethylene glycol chains effective to increase the blood circulation lifetime of the liposomes severalfold over that of liposomes in the absence of such coating, a chemotherapeutic agent in liposome-entrapped form, and covalently attached to the distal ends of a portion of said chains, antibodies or antibody fragments effective to bind to an antigen specific for said cells.

2. The method of claim 1, wherein said administering includes administration of liposomes having an attached antibody selected from the group consisting of anti-CD19 , anti-CD20 and anti-CD22, for binding to a B-cell antigen.

3. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD19 antibody, and said disorder is multiple myeloma.

4. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD19 antibody, and said disorder is acute lymphocytic leukemia.

5. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD19 antibody, and said disorder is a B-cell lymphoma.

6. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD20 antibody, and said disorder is multiple myeloma.

7. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD20 antibody, and said disorder is acute lymphocytic leukemia.

8. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD20 antibody, and said disorder is a B-cell lymphoma.

9. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD22 antibody, and said disorder is multiple myeloma.

10. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD22 antibody, and said disorder is acute lymphocytic leukemia.

11. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD22 antibody, and said disorder is a B-cell lymphoma.

12. The method of claim 2, wherein said administering includes administration to a subject having multiple myeloma, and said cells are multidrug resistant.

13. The method of claim 1, wherein said administering includes administration of liposomes having an attached antibody selected from the group consisting of anti-CD4 and anti-CD8, for binding to a T-cell antigen.

14. The method of claim 13, wherein said administering includes administration of liposomes having an attached anti-CD4 antibody, and said disorder is a T-cell lymphoma.

15. The method of claim 13, wherein said administering includes administration of liposomes having an attached anti-CD4 antibody and said disorder is acute lymphocytic leukemia.

16. The method of claim 1, wherein said administering includes administration of liposomes having a coating of polyethylene glycol having a molecular weight of between about 500-10,000 daltons.

17. The method of claim 1, wherein said administering includes administration of liposomes having a coating of polyethylene glycol having a molecular weight of between about 500-2,000 daltons.

18. The method of claim 1, wherein said administering includes administration of liposomes having doxorubicin in liposome entrapped form.

19. The method of claim 1, wherein said administering includes administration of liposomes having vincristine in liposome entrapped form.